Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: To investigate circulating levels and liver gene expression of 3 hormonal pathways associated with obesity, insulin resistance, and inflammation to identify leads towards potential diagnostic markers and therapeutic targets in patients with nonalcoholic fatty liver disease (NAFLD). Methods: We compared circulating levels of (1) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), (2) follistatins-activins (follistatin-like [FSTL]3, activin B), (3) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy-associated plasma protein [PAPP]-A) in 2 studies: (1) 18 individuals with early stage NAFLD versus 14 controls (study 1; early NAFLD study) and in (2) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs 50 controls (24 lean and 26 obese) (study 2). Liver gene expression was assessed in 22 subjects (12 controls, 5 NASH, 5 NASH-related cirrhosis). Results: Patients in early stages of NAFLD demonstrate higher fasting MPGF and lower incremental increase of glicentin during oral glucose tolerance test than controls. In more advanced stages, FSTL3 levels are higher in NASH than simple steatosis and, within NAFLD patients, in those with more severe lobular and portal inflammation. The IGF-1/intact IGFBP-3 ratio is lower in patients with liver fibrosis. Genes encoding follistatin, activin A, activin B, and the IGF-1 receptor are higher in NASH. Conclusion: MPGF and glicentin may be involved in early stages of NAFLD, whereas FSTL3 and IGF-1/intact IGFBP3 in the progression to NASH and liver fibrosis respectively, suggesting potential as diagnostic markers or therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Discovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
Irisin in patients with nonalcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Anastasilakis, A. D., Geladari, E. V., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.013 · Cited by 215
Self-citationThe role of growth hormone and insulin-like growth factor-I in the liver
Takahashi, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071447 · Cited by 193
Circulating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio
Hansen, J. S., Rutti, S., Arous, C., Clemmesen, J. O., Secher, N. H., Drescher, A., Gonelle-Gispert, C., Halban, P. A., Pedersen, B. K., Weigert, C., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3668 · Cited by 125
Inactivating hepatic follistatin alleviates hyperglycemia
Tao, R., Wang, C., Stöhr, O., Qiu, W., Hu, Y., Miao, J., Dong, X. C., Leng, S., Stefater, M., Stylopoulos, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0048-0 · Cited by 104
Hansen, J., Rinnov, A., Krogh‐Madsen, R., Fischer, C. P., Andreasen, A. S., Berg, R. M. G., Møller, K., Pedersen, B. K., & Plomgaard, P. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2415 · Cited by 71
Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis
Brown, M. L., Bonomi, L., Ungerleider, N., Zina, J., Kimura, F., Mukherjee, A., Sidis, Y., & Schneyer, A. (2011) · Obesity · doi:10.1038/oby.2011.97 · Cited by 55
Perakakis, N., Mougios, V., Fatouros, I., Siopi, A., Draganidis, D., Peradze, N., Ghaly, W., & Mantzoros, C. S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01056 · Cited by 52
Self-citation
Research works printed but not linked: 36
- Polyzos, 2016, Nonalcoholic fatty future disease, Metabolism., 65, 1007, 10.1016/j.metabol.2015.12.009 · DOI
- Polyzos, 2016, Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review, Metabolism., 65, 1297, 10.1016/j.metabol.2016.05.013 · DOI
- Stefan, 2019, Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies, Lancet Diabetes Endocrinol., 7, 313, 10.1016/S2213-8587(18)30154-2 · DOI · Paper page
- Boutari, 2018, Association of adipokines with development and progression of nonalcoholic fatty liver disease, Endocrinol Metab (Seoul)., 33, 33, 10.3803/EnM.2018.33.1.33 · DOI · Paper page
- Holst, 2016, Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor, Surg Obes Relat Dis., 12, 1236, 10.1016/j.soard.2016.02.033 · DOI · Paper page
- Feng, 2017, Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease, J Diabetes., 9, 800, 10.1111/1753-0407.12555 · DOI · Paper page
- Petit, 2017, Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD Study, J Clin Endocrinol Metab., 102, 407
- Hedger, 2013, The activins and their binding protein, follistatin—diagnostic and therapeutic targets in inflammatory disease and fibrosis, Cytokine Growth Factor Rev., 24, 285, 10.1016/j.cytogfr.2013.03.003 · DOI
- Anastasilakis, 2016, Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans, Metabolism., 65, 1459, 10.1016/j.metabol.2016.07.002 · DOI
- Moragianni, 2011, Short-term energy deprivation alters activin a and follistatin but not inhibin B levels of lean healthy women in a leptin-independent manner, J Clin Endocrinol Metab., 96, 3750, 10.1210/jc.2011-1453 · DOI
- Vamvini, 2011, Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males, J Clin Endocrinol Metab., 96, 3416, 10.1210/jc.2011-1665 · DOI · Paper page
- Brandt, 2015, Over-expression of Follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice, Metabolism., 64, 283, 10.1016/j.metabol.2014.10.007 · DOI
- Brandt, 2014, Obesity and low-grade inflammation increase plasma follistatin-like 3 in humans, Mediators Inflamm., 2014, 364209, 10.1155/2014/364209 · DOI
- de Kretser, 2012, The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair, Mol Cell Endocrinol., 359, 101, 10.1016/j.mce.2011.10.009 · DOI · Paper page
- Perakakis, 2019, Follistatins in glucose regulation in healthy and obese individuals, Diabetes Obes Metab., 21, 683, 10.1111/dom.13572 · DOI · Paper page
- Polyzos, 2016, Activin A and follistatin in patients with nonalcoholic fatty liver disease, Metabolism., 65, 1550, 10.1016/j.metabol.2016.07.009 · DOI · Paper page
- Dichtel, 2017, The association between IGF-1 levels and the histologic severity of nonalcoholic fatty liver disease, Clin Transl Gastroenterol., 8, e217, 10.1038/ctg.2016.72 · DOI · Paper page
- García-Galiano, 2007, IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients, Obes Surg., 17, 493, 10.1007/s11695-007-9087-1 · DOI
- Sumida, 2015, Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease, Hepatol Res., 45, 771, 10.1111/hepr.12408 · DOI · Paper page
- Miller, 2014, Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis, J Gastroenterol Hepatol., 29, 1839, 10.1111/jgh.12614 · DOI
- Völzke, 2009, Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample, Eur J Endocrinol., 161, 705, 10.1530/EJE-09-0374 · DOI · Paper page
- Hjortebjerg, 2018, IGFBP-4 and PAPP-A in normal physiology and disease, Growth Horm IGF Res., 41, 7, 10.1016/j.ghir.2018.05.002 · DOI
- Polyzos, 2013, Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index, Ann Hepatol., 12, 749, 10.1016/S1665-2681(19)31316-X · DOI
- Bedogni, 2006, The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population, BMC Gastroenterol., 6, 33, 10.1186/1471-230X-6-33 · DOI · Paper page
- Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology., 41, 1313, 10.1002/hep.20701 · DOI · Paper page
- Perakakis, Supplemental material related to the article entitled “Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD.” figshare. Journal contribution. 2019
- Brunt, 1999, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol., 94, 2467, 10.1111/j.1572-0241.1999.01377.x · DOI · Paper page
- Tuccinardi, 2019, Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: a six-month, randomized, placebo-controlled, double-blind clinical trial, Diabetes Obes Metab., 21, 1487, 10.1111/dom.13655 · DOI · Paper page
- Bernsmeier, 2014, Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease, Plos One., 9, e87488, 10.1371/journal.pone.0087488 · DOI · Paper page
- Raffort, 2017, Insights on glicentin, a promising peptide of the proglucagon family, Biochem Med (Zagreb)., 27, 308, 10.11613/BM.2017.034 · DOI · Paper page
- Mukherjee, 2007, FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults, Proc Natl Acad Sci U S A., 104, 1348, 10.1073/pnas.0607966104 · DOI · Paper page
- Ungerleider, 2013, Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice, Endocrinology., 154, 2025, 10.1210/en.2012-1844 · DOI
- Liu, 2015, Association of follistatin-like 3 concentrations in serum and synovial fluid with the radiographic severity of knee osteoarthritis, Int J Clin Exp Med., 8, 18884
- Kucera, 2015, Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic, Clin Chim Acta., 444, 271, 10.1016/j.cca.2015.02.036 · DOI
- Bach, 2005, IGF-binding proteins–the pieces are falling into place, Trends Endocrinol Metab., 16, 228, 10.1016/j.tem.2005.05.005 · DOI · Paper page
- Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem., 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page
Cited by
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Self-citationRelative Energy Deficiency in Sport (REDs): Endocrine Manifestations, Pathophysiology and Treatments
Angelidi, A. M., Stefanakis, K., Chou, S. H., Valenzuela-Vallejo, L., Dipla, K., Boutari, C., Ntoskas, K., Tokmakidis, P., Kokkinos, A., Goulis, D. G., et al. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae011 · Cited by 83
Self-citationAdiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD
Marques, V., Afonso, M. B., Bierig, N., Duarte-Ramos, F., Santos-Laso, Á., Jimenez-Agüero, R., Eizaguirre, E., Bujanda, L., Pareja, M. J., Luís, R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.683250 · Cited by 69
“Recent reports suggest that IGF-1 biodisponibility might be decreased during disease progression toward NASH and liver fibrosis and advance IGF-1/intact IGFBP3 ratio as a fibrosis predictor (54).”
Background
Metadata
- Authors
- Polyzos, S. A., Perakakis, N., Boutari, C., Kountouras, J., Ghaly, W., Anastasilakis, A. D., Karagiannis, A., & Mantzoros, C. S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2019-11-06
- Volume
- 105
- Issue
- 3
- Pages
- e390-e400
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2989029869
- Cited by
- 46
- References
- 10
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- National Institutes of Health (K24DK081913)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. https://app.cochat.ai/papers/10.1210/clinem/dgz172
- The paper
- Polyzos, S. A., Perakakis, N., Boutari, C., Kountouras, J., Ghaly, W., Anastasilakis, A. D., Karagiannis, A., & Mantzoros, C. S. (2020). Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgz172
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.